JP2008533198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533198A5 JP2008533198A5 JP2008502953A JP2008502953A JP2008533198A5 JP 2008533198 A5 JP2008533198 A5 JP 2008533198A5 JP 2008502953 A JP2008502953 A JP 2008502953A JP 2008502953 A JP2008502953 A JP 2008502953A JP 2008533198 A5 JP2008533198 A5 JP 2008533198A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- optionally substituted
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 28
- -1 heterocycloalkyloxy Chemical group 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 125000004404 heteroalkyl group Chemical group 0.000 claims 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims 19
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000002252 acyl group Chemical group 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 15
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 14
- 125000004103 aminoalkyl group Chemical group 0.000 claims 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000004442 acylamino group Chemical group 0.000 claims 9
- 125000003302 alkenyloxy group Chemical group 0.000 claims 9
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 9
- 125000005133 alkynyloxy group Chemical group 0.000 claims 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 9
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 9
- 125000001769 aryl amino group Chemical group 0.000 claims 9
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 9
- 125000000262 haloalkenyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 9
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 8
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 8
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004104 aryloxy group Chemical group 0.000 claims 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000232 haloalkynyl group Chemical group 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000006726 (C1-C5) alkenyl group Chemical group 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920000298 Cellophane Polymers 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000003495 Coccidiosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 1
- 206010016212 Familial tremor Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010023335 Keratitis interstitial Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 206010037075 Protozoal infections Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 241000223105 Trypanosoma brucei Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000006904 interstitial keratitis Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *c1c(*)nc2[n]1cscc2 Chemical compound *c1c(*)nc2[n]1cscc2 0.000 description 5
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66326505P | 2005-03-21 | 2005-03-21 | |
| US60/663,265 | 2005-03-21 | ||
| US75954406P | 2006-01-18 | 2006-01-18 | |
| US60/759,544 | 2006-01-18 | ||
| PCT/SG2006/000064 WO2006101455A1 (en) | 2005-03-21 | 2006-03-20 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008533198A JP2008533198A (ja) | 2008-08-21 |
| JP2008533198A5 true JP2008533198A5 (https=) | 2009-05-07 |
| JP5206405B2 JP5206405B2 (ja) | 2013-06-12 |
Family
ID=37024054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502953A Expired - Fee Related JP5206405B2 (ja) | 2005-03-21 | 2006-03-20 | イミダゾ［１，２−ａ］ピリジン誘導体：製造および医薬用途 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1863811B1 (https=) |
| JP (1) | JP5206405B2 (https=) |
| KR (1) | KR101300831B1 (https=) |
| CN (1) | CN101218238B (https=) |
| AR (1) | AR056187A1 (https=) |
| AU (1) | AU2006225355B2 (https=) |
| CA (1) | CA2602328C (https=) |
| ES (1) | ES2470766T3 (https=) |
| MX (1) | MX2007011710A (https=) |
| MY (1) | MY147647A (https=) |
| TW (1) | TW200714600A (https=) |
| WO (1) | WO2006101455A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080004311A1 (en) * | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| WO2008029152A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| WO2008036046A1 (en) * | 2006-09-20 | 2008-03-27 | S*Bio Pte Ltd | IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE |
| EA201300152A1 (ru) | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
| WO2008068392A1 (fr) * | 2006-12-07 | 2008-06-12 | Commissariat A L'energie Atomique | Nouveaux derives fluorophores imidazo [1,2-a] pyridin-3-yl-amine et leur procede de preparation |
| BRPI0809567A2 (pt) | 2007-04-10 | 2014-09-23 | Lundbeck & Co As H | Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto |
| WO2008134553A1 (en) * | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| CN101855222A (zh) * | 2007-05-10 | 2010-10-06 | 通用电气健康护理有限公司 | 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物 |
| EP2180893B1 (en) * | 2007-08-09 | 2014-11-12 | Urifer Ltd | Pharmaceutical compositions and methods for the treatment of cancer |
| DE102007040336A1 (de) | 2007-08-27 | 2009-03-05 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen |
| BRPI0817897A2 (pt) * | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| CA2724842A1 (en) * | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
| WO2010032195A1 (en) | 2008-09-16 | 2010-03-25 | Csir | Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors |
| US20110212943A1 (en) * | 2008-10-15 | 2011-09-01 | Orchid Research Laboratories Limited | Novel bridged cyclic compounds as histone deacetylase inhibitors |
| EP2601191A4 (en) * | 2010-08-03 | 2013-07-31 | Univ California | COMPOUNDS AND COMPOSITIONS FOR MITIGATING WEB DAMAGE AND LETALITY |
| US9000186B2 (en) | 2011-02-01 | 2015-04-07 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
| CA2831356A1 (en) * | 2011-03-31 | 2012-10-04 | Emblem Technology Transfer Gmbh | Imidazo [1,2-a]pyridine_compounds for use in therapy |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| CN104619707A (zh) | 2012-07-31 | 2015-05-13 | 协和发酵麒麟株式会社 | 稠环杂环化合物 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| JP2016520047A (ja) * | 2013-04-30 | 2016-07-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾールアミドのＰｄ触媒カップリング |
| EP3004088A1 (en) * | 2013-05-24 | 2016-04-13 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| CA2913785C (en) * | 2013-06-25 | 2021-08-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3062783B1 (en) | 2013-10-18 | 2020-08-12 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
| US10723705B2 (en) | 2015-08-14 | 2020-07-28 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| EP3395804B1 (en) * | 2016-09-08 | 2020-05-13 | Gachon University of Industry-Academic Cooperation Foundation | Novel spiroquinone derivative compound, production method thereof, and pharmaceutical composition for preventing or treating neurological disorders which contains same as active ingredient |
| EP4019607B1 (en) | 2020-12-22 | 2024-05-15 | Essilor International | Electrochromic compounds and optical articles containing them |
| CN113321651B (zh) * | 2021-06-22 | 2022-06-14 | 四川省医学科学院·四川省人民医院 | 吡唑并吡啶异羟肟酸类化合物、其制备方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0266890A1 (en) | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
| AU5348396A (en) * | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| CZ289425B6 (cs) * | 1998-05-20 | 2002-01-16 | Eli Lilly And Company | Imidazo[1,2-a] pyridinové sloučeniny, jejich pouľití a farmaceutický přípravek s jejich obsahem |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| CA2518318A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| TW200501897A (en) | 2003-07-10 | 2005-01-16 | Kung-Sheng Pan | Shoes electrostatically embedded with objects |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| WO2005085214A1 (ja) * | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd | ジアリール置換複素５員環誘導体 |
| US20070191334A1 (en) * | 2004-03-17 | 2007-08-16 | Altana Pharma Ag | Tricyclic imidazopyridines |
-
2006
- 2006-03-20 TW TW095109517A patent/TW200714600A/zh unknown
- 2006-03-20 MY MYPI20061225A patent/MY147647A/en unknown
- 2006-03-20 CN CN2006800092539A patent/CN101218238B/zh not_active Expired - Fee Related
- 2006-03-20 ES ES06717188.4T patent/ES2470766T3/es not_active Expired - Lifetime
- 2006-03-20 JP JP2008502953A patent/JP5206405B2/ja not_active Expired - Fee Related
- 2006-03-20 EP EP06717188.4A patent/EP1863811B1/en not_active Expired - Lifetime
- 2006-03-20 KR KR1020077023609A patent/KR101300831B1/ko not_active Expired - Fee Related
- 2006-03-20 WO PCT/SG2006/000064 patent/WO2006101455A1/en not_active Ceased
- 2006-03-20 AU AU2006225355A patent/AU2006225355B2/en not_active Ceased
- 2006-03-20 CA CA2602328A patent/CA2602328C/en not_active Expired - Fee Related
- 2006-03-20 AR ARP060101088A patent/AR056187A1/es unknown
- 2006-03-20 MX MX2007011710A patent/MX2007011710A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533198A5 (https=) | ||
| JP2009507829A5 (https=) | ||
| US8877933B2 (en) | Thermodynamically stable form of a tosylate salt | |
| US9174969B2 (en) | Indoline scaffold SHP-2 inhibitors and cancer treatment method | |
| JP2012515166A5 (https=) | ||
| JP2014525426A5 (https=) | ||
| JP2012526082A5 (https=) | ||
| JP2016506387A5 (https=) | ||
| JP2010526145A5 (https=) | ||
| JP2013542929A5 (https=) | ||
| JP2013500314A5 (https=) | ||
| JP2009535307A5 (https=) | ||
| JP2015503527A5 (https=) | ||
| JP2020514323A5 (https=) | ||
| DE60138658D1 (de) | Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria | |
| JP2010511626A5 (https=) | ||
| JP2010524963A5 (https=) | ||
| CN101815518A (zh) | 用于神经保护的nmda受体拮抗剂 | |
| JP2011525535A5 (https=) | ||
| JP2014503525A5 (https=) | ||
| JP2012515724A5 (https=) | ||
| JP2004516278A (ja) | 一酸化窒素合成酵素阻害物質であるリン酸塩 | |
| RU2004114263A (ru) | Производные тиазола, имеющие антагонистичекую агонистическую или частично агонистическую св1-активность | |
| RS51861B2 (sr) | Heterociklični inhibitori mek-a | |
| JP2008521831A5 (https=) |